ESMO 2017: Docetaxel and abiraterone acetate plus prednisolone equally improved survival in patients with high-risk prostate cancer: first results from the STAMPEDE trial


  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A subanalysis of the STAMPEDE trial found that docetaxel and abiraterone acetate plus prednisolone equally improved survival when added to long-term hormone therapy in patients with high-risk prostate cancer.
  • Either drug is acceptable and choice may depend on availability.

Wh...